Shares of N4 Pharma PLC (LON:N4P) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 32.23 ($0.45) and last traded at GBX 29.84 ($0.41), with a volume of 2002118 shares traded. The stock had previously closed at GBX 28.75 ($0.40).

Separately, Beaufort Securities restated a “speculative buy” rating and issued a GBX 12 ($0.17) price objective on shares of N4 Pharma in a research note on Thursday, November 30th.

ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at

N4 Pharma Company Profile

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.

Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with's FREE daily email newsletter.